Endothelial dysfunction and angiogenesis: what is missing from COVID-19 and cannabidiol story? - Journal of Cannabis Research
Ashtar Nakhaei, School Of Medicine, Tehran University Of Medical Sciences, Tehran, Najarian, Medical Biology Research Center, Health Technology Institute, Kermanshah University Of Medical Sciences, Kermanshah, Farzaei
Angiogenesis and endothelial dysfunction in COVID-19 Recently, upon our review research on the role of angiogenesis and endothelial dysfunction in COVID-19 (Norooznezhad and Mansouri 2021), we found that among many EC surface receptors, angiotensin-converting enzyme 2 (ACE2) receptor associates most with COVID-19 infection. Cannabidiol, angiogenesis, and endothelial cells As mentioned, cannabinoids have been studied for their strong anti-inflammatory potentials and ability to inhibit/decrease various important pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α. Endothelial cell dysfunction and some of the pro-angiogenic factors are directly associated with ARDS (Ackermann et al. 2020; Norooznezhad and Mansouri 2021). 1 Short review on the potential of cannabidiol on pathologic angiogenesis and endothelialitis. A significant decrease was observed in TNF-α levels from their PBMCs upon previous exposure to CBD compared to the cells collected before CBD treatment (Hobbs et al. 2020).
Tags:
- Cannabidiol
- Angiogenesis
- Endothelium
- Cannabinoid
- Tumor necrosis factor
- COVID-19
- Cannabinoid receptor type 2
- Angiotensin-converting enzyme 2
- Cytokine
- Interleukin 6
- Inflammation
- Vascular endothelial growth factor
- Neurochemistry
- Cell signaling
- Biochemistry
- Medicine
- Clinical medicine
- Cell biology
- Medical specialties